PMID- 8822127
OWN - NLM
STAT- MEDLINE
DCOM- 19961119
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 81
IP  - 2 Suppl
DP  - 1996
TI  - Coronary heart disease, unstable angina, PTCA: new indications for low molecular 
      weight heparins?
PG  - S47-51
AB  - Unstable angina in patients with coronary heart disease carries a high risk of 
      myocardial infarction (MI) and death. Partial thrombotic occlusions of coronary 
      arteries are a major causal factor in the development of unstable angina and 
      consecutive thrombotic occlusions may lead to MI. Treatment with unfractionated 
      heparin (UFH) has been shown to significantly reduce the frequency of anginal 
      attacks, but not to affect the frequency of MI, PTCA and death within one month. 
      Prolonged treatment with low molecular weight heparins (LMWHs) may improve the 
      outcome in patients with unstable angina. New clinical studies in this area seem 
      promising. In the prevention of early reocclusions after PTCA LMWHs may be more 
      effective than UFH. Late restenosis after PTCA within 6 months occurs in 25-35% 
      of patients. To date, no effective prophylaxis exists. In a recent trial, 
      short-term treatment with a LMWH had no preventive effect on late restenoses. 
      Ongoing trials with long-term treatment may lead to better results. In the near 
      future long-term treatment, up to six months, with a LMWH alone or in combination 
      with a platelet function inhibitor, possibly with reduced doses of both drugs, 
      may reduce the frequency of restenosis.
FAU - Breddin, H K
AU  - Breddin HK
AD  - International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Angina, Unstable/*drug therapy/etiology
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Animals
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Coronary Disease/complications/*drug therapy/etiology/prevention & control
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Recurrence
MH  - Risk Factors
RF  - 21
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(95)00229-4 [doi]
PST - ppublish
SO  - Thromb Res. 1996;81(2 Suppl):S47-51. doi: 10.1016/0049-3848(95)00229-4.